Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

FHS
June 12, 2024
10:52 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

UK biotech brings in $226M Series C

Apollo Therapeutics is reeling in a $226.5 million Series C round, the biotech said Wednesday. The financing is two-pronged: It aims to advance Apollo’s clinical

September 7, 2023

Eli Lilly’s chief scientist on new obesity drug data, gene editing, and a potential new heart drug

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about

November 13, 2023

Pregnant smokers who use e-cigarettes more likely to quit smoking later in pregnancy

The risks of smoking during pregnancy for both maternal and fetal health are well documented, but only about half of pregnant people quit smoking on

September 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.